ArticleCPT: pharmacometrics & systems pharmacology2021

PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients.

Stefan Willmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.